CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 404 enrolled
Drug / intervention
Shared Care +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03244826
NCT03244826N/ACompleted

Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation

Dana-Farber Cancer Institute·interventional·Posted Aug 10, 2017·Updated Aug 16, 2024

In Brief

A clinical study evaluating Shared Care and Standard Care for Other Cancer. Completed, enrolled 404 participants across 9 sites.

Detailed Summary

This research study aims to evaluate the effectiveness of allowing patients who have had a hematopoietic cell transplant to receive some of their post-transplant care with a local oncologist rather than returning to the transplant center for all of their follow-up.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOther Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 10, 2017
Enrollment StartJan 1, 2018
Primary CompletionAug 22, 2022
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 8.9 years ago

Interventions

Shared Careother

Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team

Standard Careother

The usual care provided by the transplant center at DFCI.